Cancer Family
Embryonal Neoplasm
CI-CAN-00000013Explore in graph →
Loading cancer entity…
Cancer Family
CI-CAN-00000013Explore in graph →
Variants & evidence
172 evidence items mapped to this entity or its descendants, grouped by molecular profile, then therapy. 50 items per page.
| Therapy | Cancer | Type | Level | Direction · significance | Rating (1–5) | Status | Evidence | Source |
|---|---|---|---|---|---|---|---|---|
| SMARCB1 LOSS OF NUCLEAR PROTEIN EXPRESSION2 | ||||||||
| (diagnostic) | Cribriform Neuroepithelial Tumor | Diagnostic | C | Supports Positive | 3 | accepted | EID12327This is the first case report of cribriform neuroepithelial tumor (CRINET), a rare brain cancer identified in a 26-month-old girl and a 10-month-old boy, affecting the third and fourth ventricles. His… (full text at CIViC) PMID 19915490 · Hasselblatt et al., 2009 · Open in CIViC | civic |
| 〃 | Cribriform Neuroepithelial Tumor | Diagnostic | C | Supports Positive | 3 | accepted | EID12328This study explored the molecular features of cribriform neuroepithelial tumors (CRINET) using multiplex ligation-dependent probe amplification (MLPA) and molecular inversion profiling (MIP) assays al… (full text at CIViC) PMID 26352987 · Gessi et al., 2015 · Open in CIViC | civic |
| SMO D473H3 | ||||||||
| Patidegib | MedulloblastomaCURATED_BROADER | Predictive | D | Supports Sensitivity Response | 3 | accepted | EID1099Saridegib treatment induced tumor reduction and significantly prolonged survival in a Shh-driven mouse medulloblastoma model, and was found to be active in cells with the D473H point mutation. PMID 22550175 · Lee et al., 2012 · Open in CIViC | civic |
| Vismodegib | MedulloblastomaCURATED_BROADER | Predictive | C | Supports Resistance | 3 | accepted | EID745In this case report, the D473H mutation was reported as an acquired mechanism of resistance to the hedgehog pathway inhibitor GDC-0449 (vismodegib). PMID 19726788 · Yauch et al., 2009 · Open in CIViC | civic |
| 〃 | MedulloblastomaCURATED_BROADER | Predictive | D | |||||
| SNCAIP Tandem duplication1 | ||||||||
| (diagnostic) | Medulloblastoma, Non-WNT/Non-SHH, Group 4 | Diagnostic | B | Supports Positive | 3 | submitted | EID11193Analysis of somatic copy number alterations (SCNAs) in 1087 medulloblastoma tumours identified a recurrent tandem duplication of SNCAIP that was restricted to Group 4 medulloblastoma. SNCAIP duplicati… (full text at CIViC) PMID 22832581 · Northcott et al., 2012 · Open in CIViC | civic |
| STAG2 MUTATION1 | ||||||||
| (prognostic) | Bone Ewing SarcomaALIAS | Prognostic | B | Supports Poor Outcome | 4 | accepted | EID1697In a study of 96 Ewing sarcoma tumors, 15% showed heterogenous loss of STAG2 expression in IHC analysis. Of those with STAG2 expression loss, 88% presented with metastatic disease compared to only 27… (full text at CIViC) PMID 25186949 · Crompton et al., 2014 · Open in CIViC | civic |
| SUFU Deletion1 | ||||||||
| Sonidegib | MedulloblastomaCURATED_BROADER | Predictive | D | Supports Resistance | 3 | submitted | EID5324In a sonic hedgehog driven medulloblastoma patient derived xenograft harbouring a SUFU deletion, SMO inhibition with LDE225 (Sonidegib) did not affect cell proliferation. PMID 24651015 · Kool et al., 2014 · Open in CIViC | civic |
| TBX2 Expression1 | ||||||||
| (diagnostic) | Poorly Differentiated Chordoma | Diagnostic | B | Supports Positive | 2 | rejected | EID11171All chordomas including 14 conventional chordomas and 7 poorly differentiated chordomas exhibited nuclear expression of brachyury (TBX2) by IHC whereas only 2 of 30 atypical teratoid/rhabdoid tumors w… (full text at CIViC) PMID 27067307 · Hasselblatt et al., 2016 · Open in CIViC | civic |
| TBXT Amplification1 | ||||||||
| (oncogenic) | Chordoma | Oncogenic | D | Supports Oncogenicity | 1 | submitted | EID11173shRNA knockdown of TBXT in the JHC7 chordoma cell line with TBXT amplification resulted in differentiation and growth arrest. PMID 21699479 · Hsu et al., 2011 · Open in CIViC | civic |
| TBXT Expression2 | ||||||||
| (diagnostic) | Poorly Differentiated Chordoma | Diagnostic | B | Supports Positive | 2 | submitted | EID11172All chordomas including 14 conventional chordomas and 7 poorly differentiated chordomas exhibited nuclear expression of brachyury (TBXT) by IHC whereas only 2 of 30 atypical teratoid/rhabdoid tumors w… (full text at CIViC) PMID 27067307 · Hasselblatt et al., 2016 · Open in CIViC | civic |
| Nivolumab | Chordoma | Predictive | C | Supports Sensitivity Response | 3 | submitted | EID12067This pediatric patients harboured a chordoma with high TBXT expression when compared with TCGA and POG570 data, and a high CD8+ infiltration score. The patient was treated with nivolumab, and experien… (full text at CIViC) PMID 34931022 · Williamson et al., 2021 · Open in CIViC | civic |
| TBXT Gain2 | ||||||||
| (oncogenic) | Chordoma | Oncogenic | D | Supports Oncogenicity | 1 | submitted | EID11174Knockdown of TBXT in the U-CH1 chordoma cell line with polysomy of chromosome 6 decreased proliferation and induced a senescence-like phenotype. PMID 21171078 · Presneau et al., 2011 · Open in CIViC | civic |
| 〃 | Chordoma | Oncogenic | D | Supports Oncogenicity | 1 | submitted | EID11175Knockdown of TBXT in the U-CH1 chordoma cell line with polysomy of chromosome 6 decreased proliferation and induced a senescence-like phenotype. PMID 21171078 · Presneau et al., 2011 · Open in CIViC | civic |
| TP53 Mutation6 | ||||||||
| (predisposing) | Medulloblastoma, SHH-Activated, TP53-MutantALIAS | Predisposing | B | Supports Predisposition | 5 | submitted | EID8346This international, multicenter study analyzed patients with medulloblastoma (MB) from both retrospective and prospective cohorts in order to identify consensus MB predisposition genes. A total of 102… (full text at CIViC) PMID 29753700 · Waszak et al., 2018 · Open in CIViC | civic |
| (prognostic) | Medulloblastoma, SHH-Activated | Prognostic | B | Supports Poor Outcome | 5 | accepted | EID8347In the childhood (≥4.3 years) SHH-MB subgroup, TP53 mutations (n=13) are associated with shorter progression-free survival (PFS) compared to the no mutation group (n=35) (HR, 3.47; 95% CI, 1.29 to 9.3… (full text at CIViC) PMID 28545823 · Schwalbe et al., 2017 · Open in CIViC | civic |
| 〃 | MedulloblastomaCURATED_BROADER | Prognostic | ||||||
| Deletion + TP53 Mutation1 | ||||||||
| (prognostic) | Kidney Wilms TumorALIAS | Prognostic | B | Supports Poor Outcome | 3 | submitted | EID1283540 diffuse anaplasia in Wilms tumours (DAWT) samples were tested using copy number (n = 32) and gene expression (n = 36) arrays. 22 had TP53 mutations and 20 of these also had 17p loss. An increased r… (full text at CIViC) PMID 25313908 · Maschietto et al., 2014 · Open in CIViC | civic |
| TP53 Overexpression1 | ||||||||
| (prognostic) | Kidney Wilms TumorALIAS | Prognostic | B | Supports Poor Outcome | 3 | accepted | EID894544 archival FFPE samples from confirmed cases of Wilms tumor with mean age 3 years 2 months, and taken from the most histologically aggressive parts of each tumor, were stained with p53 monoclonal ant… (full text at CIViC) PMID 21525573 · Jadali et al., 2011 · Open in CIViC | civic |
Data updated 16 hours agoSource updated unknownsource: civic (CC0)
Evidence levels, directions and ratings are those assigned by CIViC curators. "Submitted" items have not completed curation review. This is not treatment guidance.
| — |
| submitted |
EID4427In an in vitro study, a C3H10T1/2 cell line expressing SMO D473H mutation, demonstrated resistance to vismodegib treatment (IC50: 3,000,000 nmol/L vs. 20 nmol/L) compared to C3H10T1/2 cells expressing… (full text at CIViC) PMID 21123452 · Dijkgraaf et al., 2011 · Open in CIViC |
| civic |
| B |
| Supports Poor Outcome |
| 4 |
| submitted |
EID7963This study showed that patients with TP53 mutated medulloblastoma (8/49, 16%) exhibited worse prognosis compared to those with wildtype medulloblastoma (41/49, 84%). A 5-year overall survival of 0% wa… (full text at CIViC) PMID 20142599 · Tabori et al., 2010 · Open in CIViC |
| civic |
| 〃 | MedulloblastomaCURATED_BROADER | Prognostic | B | Supports Poor Outcome | 4 | submitted | EID7964This study examined the prognostic implication of TP53 mutation status in different molecular subgroups of medulloblastoma. A discovery cohort of 397 patients and a validation cohort of 156 cases were… (full text at CIViC) PMID 23835706 · Zhukova et al., 2013 · Open in CIViC | civic |
| (diagnostic) | Medulloblastoma, SHH-Activated, TP53-MutantALIAS | Diagnostic | B | Supports Positive | 4 | submitted | EID8345One of the goals of this study is to understand the biology of the sonic-hedgehog subgroup of medulloblastoma (SHH-MB) across different age groups. A large cohort of patients (n=133) with SHH-MB, incl… (full text at CIViC) PMID 24651015 · Kool et al., 2014 · Open in CIViC | civic |
| Vismodegib | Medulloblastoma, SHH-Activated, TP53-MutantALIAS | Predictive | C | Does Not Support Sensitivity Response | 3 | submitted | EID8348Two phase II studies (PBTC-025B, n=31, age ≥ 22 years; PBTC-032, n=12, age 3-21 years) assessed the targeted efficacy of vismodegib, an SMO inhibitor, in patients with recurrent sonic hedgehog subgrou… (full text at CIViC) PMID 26169613 · Robinson et al., 2015 · Open in CIViC | civic |